The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...

Analysts have given Stoke Therapeutics a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $29.0, indicating a potential 121.37% upside.

As I filled out a waiver so he could enter the store’s small play area, I noticed I was the only parent present.” ...

As heatwaves become more intense with climate change, scientists are racing to understand how extreme heat changes the way ...

“He’s just, as you can see, unstoppable,” said Noah’s dad, Andrew Beighley. “For him to still be that happy is something else,” agreed Noah’s mom, Shanice Beighley. Noah is at risk of having a serious ...

HONG KONG SAR - Media OutReach Newswire - 8 August 2025 - Bora Pharmaceuticals (TWSE: 6472) today announced its financial ...

Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 ...

Q2 2025 Earnings Call Transcript August 5, 2025 Harmony Biosciences Holdings, Inc. misses on earnings expectations. Reported ...

With Prince William’s daughter, Princess Charlotte, also in attendance for the final there was speculation that she would be ...

In February 2025, Biogen Inc. (NASDAQ:BIIB) formed a partnership with Stoke Therapeutics to develop zorevunersen for Dravet syndrome, a rare genetic epilepsy, further strengthening its rare ...

As heatwaves become more intense with climate change, scientists are racing to understand how extreme heat changes the way ...